New Data from SPRAVATO™ (esketamine) CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent - PRNewswire

Submitted by Anonymous (not verified) on Mon, 09/09/2019 - 13:00

New Data from SPRAVATO™ (esketamine) CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent  PRNewswireTITUSVILLE, N.J., Sept. 9, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from two ...